04:14 PM EDT, 03/12/2026 (MT Newswires) -- Mineralys Therapeutics ( MLYS ) reported a Q4 loss late Thursday of $0.40 per diluted share, narrowing from a loss of $0.98 a year earlier.

Analysts polled by FactSet expected a loss of $0.52.

As of Dec. 31, the company had cash and cash equivalents of $656.6 million, expected to be adequate to fund its planned clinical trials and support corporate operations through 2028.